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Poster Session I S249(p 5 0.01). Likewise, the probability or relapse was highest in the
MK1 group (72%) as compared to the MK- group (37%), the CN
group (24%), or the CBF group (14%) (p 5 0.001). There was no
statistically significant difference in non-relapse mortality between
the four groups.
Conclusions:Our results indicate that cytogenetics is still one of the
most important prognostic factors. In particular, the presence of
a monosomal karyotype provides a strong negative prognostic pre-
diction for patients with AML undergoing alloSCT. These patients
should be referred to alloSCT in early in CR1.260
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Lymphoid leukemia and Non-Hodgkin’s lymphoma (NHL) are
heterogeneous diseases, which require various treatment modalities.
Although the success of hematopoietic stem cell transplantation
(HSCT) for myeloid leukemia has been well documented in the
last decade, advances in lymphoid malignancies have been modest
and the efficacy of HSCT for these diseases merits further study.
To identify potential efficacious pretransplant conditioning therapy
for these diseases, we performed in vitro cellular studies on the pos-
sible synergistic cytotoxicity of the DNA-alkylating agent busulfan
(Bu) and nucleoside analogs (NA) clofarabine (Clo), fludarabine
(Flu) and gemcitabine (Gem). Daudi (B cell lymphoblast), J45.01
(T cell lymphoblast) and U937 (monocytic/lymphoblast) cells were
exposed to these drugs, either individually or in combinations, and
analyzed for cell survival by the MTT assay and for protein level
and modifications by Western blot analysis. The three cell lines ex-
hibited different drug sensitivities as suggested by the IC50 values:
Daudi – 40 mM Bu, 80 nM Clo, 30 mM Flu and 2 nM Gem; J45.01
– 100 mM Bu, 60 nM Clo, 0.8 mM Flu and 25 nM Gem; U937 -
160 mM Bu, 20 nM Clo, 1.2 mM Flu and 70 nM Gem. Synergistic
cytotoxicities were observed when the drugs were combined at
IC10 – IC20 concentrations with U937 cells being the most sensitive.
Exposure of cells to [Gem1Clo1Bu], [Gem1Flu1Bu] or [Clo1-
Flu1Bu] for 4 days resulted in 5%-15% survival of U937 cells,
20%-50% of Daudi cells and 45%-80% of J45.01 cells. The effects
of these drug combinations on cell survival are consistent withDNA-
damage response as indicated by the phosphorylation of H2AX,
ATM and SMC1 proteins, and cleavage of PARP-1. The observed
methylations of histone 3 may suggest chromatin remodeling which
may contribute to the pronounced activity of [NA1Bu] combina-
tions. Interestingly, [twoNA1 Bu] combinations are muchmore ef-
ficacious than [one NA1 Bu]. Exposure of Daudi, J45.01 and U937
cells to [Gem1Bu] for 4 days resulted in 85%, 100% and 78% cell
survival, respectively. Similar exposure to [Gem1Clo1Bu] resulted
in 50%, 60% and 5% survival and exposure to [Gem1Flu1Bu] re-
sulted in 20%, 80% and 6% survival of Daudi, J45.01, and U937
cells, respectively. Our results suggest that combination of two NA
with Bu may be more active than Bu plus one NA. The findings sup-
port the introduction of [twoNA1 Bu] as part of pretransplant con-
ditioning regimen for advanced, aggressive lymphoid malignancies.261
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Introduction: The Philadelphia chromosome translocation ([Ph1)
is the most frequent cytogenetic abnormality detected in adult ALL.
Ph1 patients are classified as high-risk, with allogeneic hematopoi-
etic stem cell transplantation (alloHCT) considered the best chance
for cure. The role of autologous transplantation (autoHCT) in the
treatment of these patients remains controversial. More recently, ty-rosine kinase inhibitors (TKIs) have shown promise in treating Ph1
ALL. The long-term outcomes with TKI’s plus chemotherapy re-
main poor, consequently transplantation is still considered standard.
AtUCSF, Ph1ALLpatients without histocompatible donors are of-
fered autoHCT. In this study we retrospectively analyzed adult ALL
patients undergoing alloHCT and autoHCT at UCSF from 1986 to
2009 to identify factors influencing outcome.
Patients and Methods: 121 patients diagnosed with ALL under-
went autoHCT or alloHCT at UCSF since 1986. 42 patients were
Ph positive; based on cytogenetic and/or molecular methods. The
mean age at transplant was 36 overall (15-64), and 43 for Ph1 pa-
tients (23-64). Patients received autoHCT or alloHCT based on do-
nor availability. Overall, 43 patients underwent autoHCT, and 78
underwent alloHCT. For the Ph1 subgroup, 13 and 29 received au-
toHCT and alloHCT respectively. Conditioning consisted of either
total body irradiation (TBI) with etoposide and/or cyclophospha-
mide; or fludarabine with busulfan. AlloHCT patients received stan-
dard GVHD prophylaxis, and all patients received ID prophylaxis.
Results: The median disease-free survival (DFS) overall was 1.59
years for patients receiving autoHCT and 1.7 years for those receiv-
ing alloHCT. The 5-year probability of DFS was 38% for au-
toHCT, and 44% for alloHCT with treatment-related mortality
of 9% and 36%, respectively. In the subset of Ph1 patients, 5-year
probability of DFS was 58% and 40%, respectively, with no signifi-
cant difference detected. Improved DFS with noted following TKI
use (70% in the autologous group, n10; 58% in the allogeneic group,
n17). Status at transplantation correlated with probability of DFS.
TBI-based regimens and age were not found to influence outcomes.
Conclusion:Our data support the use of alloHCT for the treatment
of ALL, including Ph1 patients. The data with autoHCT are en-
couraging, with impressive results found following the addition of
TKI therapy. A larger Phase II study evaluating the role of autoHCT
in PH1 ALL appears warranted.262
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The purine nucleoside analogs fludarabine (Flu) and clofarabine
(Clo) were recently shown to have synergistic cytotoxic activity
when combined with busulfan (Bu) in AML cell lines and in primary
explanted AML cells. We attributed most of this synergism to ATM
pathway activation and chromatin remodeling. We have now ex-
tended these studies to include gemcitabine (Gem), a pyrimidine nu-
cleoside analog, and determined their efficacy and synergism in
myeloid cells including two AML cell lines (KBM3/Bu2506 and
OCI-AML3) and two CML cell lines (B5/Bu2506 and KBM5).
Combination of sub-lethal (IC10 – IC20) concentrations of the re-
spective agents [Flu1Clo1Bu] was demonstrated to be synergisti-
cally cytotoxic to both AML cell lines and KBM5 but less active
against B5/Bu2506 cells. Similar results were obtained when cells
were exposed to sub-lethal concentations (IC10 – IC20) of
[Clo1Gem1Bu] and [Flu1Gem1Bu] suggesting that replacement
of either Clo or Flu with Gem in triple-drug exposure did not result
in significantly different phenotypic responses.Western blot analysis
indicates DNA-damage response as shown by the activation of ATM
and apoptotic pathways in cells exposed to triple-drug combinations.
Since chromatin remodeling is involved in the efficacy of [Clo1
Flu1Bu] in AML cells, we hypothesize that similar mechanism is in-
volved in the efficacy of [Clo1Gem1Bu] and [Flu1Gem1Bu]. Al-
though limited in sample size, our present and published studies
suggest that combination of Bu with two nucleoside analogs as
part of pretransplant therapy will be more efficacious against
AML. However, the relative resistance of B5/Bu2506 cells and sensi-
tivity of KBM5 cells to triple-drug combinations suggests varied re-
sponses of CML cells. Further experiments using additional CML
cell lines and primary explanted CML cells are warranted to define
the relevance of [nucleoside analogs1Bu] combinations in pretrans-
plant regimen for CML patients who will undergo hematopoietic
